Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Neoleukin Therapeutics, Inc. (AQXP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
8-K
| Quarterly results |
| 05/09/2022 |
8-K
| Quarterly results |
| 03/01/2022 |
8-K
| Quarterly results |
| 11/04/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 05/12/2021 |
8-K
| Quarterly results |
| 03/25/2021 |
8-K
| Quarterly results |
| 11/09/2020 |
8-K
| Quarterly results |
| 08/12/2020 |
8-K
| Quarterly results |
| 05/06/2020 |
8-K
| Quarterly results |
| 03/12/2020 |
8-K
| Quarterly results |
| 11/13/2019 |
8-K
| Quarterly results |
| 11/07/2018 |
8-K
| Quarterly results|
Docs:
|
"SIGNATURE",
"Aquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results VANCOUVER, British Columbia, November 7, 2018 — Aquinox Pharmaceuticals , Inc. , a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the third quarter ending September 30, 2018. “We ended the third quarter with $86.7 million in cash and cash equivalents and have taken additional steps to reduce expenditures, including further reductions planned in the fourth quarter, to optimize our cash reserves while we evaluate strategic alternatives,” said David Main, President & CEO of Aquinox. Recent Business Updates Company Restructuring. In July 2018, Aquinox announced a restruct..." |
|
| 08/08/2018 |
8-K
| Quarterly results|
Docs:
|
"FORM 8-K",
"Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results VANCOUVER, British Columbia, August 8, 2018 — Aquinox Pharmaceuticals , Inc. , a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the second quarter ending June 30, 2018. “At the end of last quarter, we announced that the Phase 3 clinical trial of our lead drug candidate, rosiptor, in interstitial cystitis/bladder pain syndrome failed to meet its primary endpoint. As a result, we've halted all development activities for rosiptor and significantly reduced the size of our organization,” said David Main, President & CEO of Aquinox. “We are currently evaluating our interna..." |
|
| 05/08/2018 |
8-K
| Quarterly results|
Docs:
|
"SIGNATURE",
"Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results VANCOUVER, British Columbia, May 8, 2018 — Aquinox Pharmaceuticals , Inc. , a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the first quarter ending March 31, 2018. “The first quarter was important as we surpassed recruitment targets and completed enrollment of the LEADERSHIP 301 Phase 3 clinical trial in subjects with interstitial cystitis/bladder pain syndrome ,” said David Main, President & CEO of Aquinox. “IC/BPS remains an area of high unmet medical need with few effective treatments available. We remain on track for sharing the topline results of..." |
|
| 03/12/2018 |
8-K
| Quarterly results |
| 11/08/2017 |
8-K
| Quarterly results|
Docs:
|
"Number Description 99.1 Press Release of Aquinox Pharmaceuticals, Inc. dated November 8, 2017 SIGNATURE",
"Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results Vancouver, British Columbia - November 8, 2017 - — Aquinox Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today reported financial results for the third quarter ending September 30, 2017 and provided a corporate update. “Our LEADERSHIP 301 clinical trial in Interstitial Cystitis/Bladder Pain Syndrome continues to enroll on pace to meet our guidance of top-line data in the third quarter of 2018,” said David Main, President & CEO of Aquinox. “In addition, November marks Bladder Health Month in the U.S. and we are pleased to be supporting greater awareness of IC/BPS with our continued support for the Inte..." |
|
| 08/08/2017 |
8-K
| Quarterly results |
| 05/09/2017 |
8-K
| Form 8-K - Current report |
| 03/09/2017 |
8-K
| Form 8-K - Current report |
| 11/09/2016 |
8-K
| Form 8-K - Current report |
| 08/04/2016 |
8-K
| Form 8-K - Current report |
| 05/10/2016 |
8-K
| Form 8-K - Current report |
| 03/14/2016 |
8-K
| Form 8-K - Current report |
| 11/10/2015 |
8-K
| Form 8-K - Current report |
| 08/06/2015 |
8-K
| Form 8-K - Current report |
| 05/12/2015 |
8-K
| Form 8-K - Current report |
| 03/16/2015 |
8-K
| Form 8-K - Current report |
| 11/04/2014 |
8-K
| Form 8-K - Current report |
| 08/11/2014 |
8-K
| Form 8-K - Current report |
| 05/13/2014 |
8-K
| Form 8-K - Current report |
|
|